201 related articles for article (PubMed ID: 22540223)
41. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.
Moore CL; Osaki-Kiyan P; Haque NZ; Perri MB; Donabedian S; Zervos MJ
Clin Infect Dis; 2012 Jan; 54(1):51-8. PubMed ID: 22109947
[TBL] [Abstract][Full Text] [Related]
42. Combination of Vancomycin and β-Lactam Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Pilot Multicenter Randomized Controlled Trial.
Davis JS; Sud A; O'Sullivan MVN; Robinson JO; Ferguson PE; Foo H; van Hal SJ; Ralph AP; Howden BP; Binks PM; Kirby A; Tong SYC; ; ; Tong S; Davis J; Binks P; Majumdar S; Ralph A; Baird R; Gordon C; Jeremiah C; Leung G; Brischetto A; Crowe A; Dakh F; Whykes K; Kirkwood M; Sud A; Menon M; Somerville L; Subedi S; Owen S; O'Sullivan M; Liu E; Zhou F; Robinson O; Coombs G; Ferguson P; Ralph A; Liu E; Pollet S; Van Hal S; Foo H; Van Hal S; Davis R
Clin Infect Dis; 2016 Jan; 62(2):173-180. PubMed ID: 26349552
[TBL] [Abstract][Full Text] [Related]
43. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
Mogle BT; Steele JM; Seabury RW; Dang UJ; Kufel WD
Int J Antimicrob Agents; 2018 Dec; 52(6):805-810. PubMed ID: 30176357
[TBL] [Abstract][Full Text] [Related]
44. Establishment of an AUC
Chavada R; Ghosh N; Sandaradura I; Maley M; Van Hal SJ
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242672
[TBL] [Abstract][Full Text] [Related]
45. Methicillin-resistant Staphylococcus aureus (MRSA) staphylococcal cassette chromosome mec genotype effects outcomes of patients with healthcare-associated MRSA bacteremia independently of vancomycin minimum inhibitory concentration.
Chen SY; Liao CH; Wang JL; Chiang WC; Lai MS; Chie WC; Chen WJ; Chang SC; Hsueh PR
Clin Infect Dis; 2012 Nov; 55(10):1329-37. PubMed ID: 22911641
[TBL] [Abstract][Full Text] [Related]
46. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
Walraven CJ; North MS; Marr-Lyon L; Deming P; Sakoulas G; Mercier RC
J Antimicrob Chemother; 2011 Oct; 66(10):2386-92. PubMed ID: 21775337
[TBL] [Abstract][Full Text] [Related]
47. Empirical combination of a β-lactam to vancomycin may not improve outcomes of methicillin-susceptible Staphylococcus aureus bacteremia, compared to vancomycin monotherapy.
Park GE; Ko JH; Cho SY; Ha YE; Lee NY; Kang CI; Chung DR; Song JH; Peck KR
Eur J Clin Microbiol Infect Dis; 2017 Jul; 36(7):1091-1096. PubMed ID: 28078559
[TBL] [Abstract][Full Text] [Related]
48. Nephrotoxicity of vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
Shen WC; Chiang YC; Chen HY; Chen TH; Yu FL; Tang CH; Sue YM
Nephrology (Carlton); 2011 Nov; 16(8):697-703. PubMed ID: 21707841
[TBL] [Abstract][Full Text] [Related]
49. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization.
Brown J; Brown K; Forrest A
Antimicrob Agents Chemother; 2012 Feb; 56(2):634-8. PubMed ID: 22123681
[TBL] [Abstract][Full Text] [Related]
50. Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.
Tong SYC; Lye DC; Yahav D; Sud A; Robinson JO; Nelson J; Archuleta S; Roberts MA; Cass A; Paterson DL; Foo H; Paul M; Guy SD; Tramontana AR; Walls GB; McBride S; Bak N; Ghosh N; Rogers BA; Ralph AP; Davies J; Ferguson PE; Dotel R; McKew GL; Gray TJ; Holmes NE; Smith S; Warner MS; Kalimuddin S; Young BE; Runnegar N; Andresen DN; Anagnostou NA; Johnson SA; Chatfield MD; Cheng AC; Fowler VG; Howden BP; Meagher N; Price DJ; van Hal SJ; O'Sullivan MVN; Davis JS;
JAMA; 2020 Feb; 323(6):527-537. PubMed ID: 32044943
[TBL] [Abstract][Full Text] [Related]
51. Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation.
Moise PA; Culshaw DL; Wong-Beringer A; Bensman J; Lamp KC; Smith WJ; Bauer K; Goff DA; Adamson R; Leuthner K; Virata MD; McKinnell JA; Chaudhry SB; Eskandarian R; Lodise T; Reyes K; Zervos MJ
Clin Ther; 2016 Jan; 38(1):16-30. PubMed ID: 26585355
[TBL] [Abstract][Full Text] [Related]
52. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia.
Khatib R; Saeed S; Sharma M; Riederer K; Fakih MG; Johnson LB
Eur J Clin Microbiol Infect Dis; 2006 Mar; 25(3):181-5. PubMed ID: 16505987
[TBL] [Abstract][Full Text] [Related]
53. Treating Central Catheter-Associated Bacteremia Due to Methicillin-Resistant Staphylococcus aureus: Beyond Vancomycin.
Holt S; Thompson-Brazill KA; Sparks ER; Lipetzky J
Crit Care Nurse; 2016 Aug; 36(4):46-57. PubMed ID: 27481801
[TBL] [Abstract][Full Text] [Related]
54. Method-specific performance of vancomycin MIC susceptibility tests in predicting mortality of patients with methicillin-resistant Staphylococcus aureus bacteraemia.
Chen SY; Liao CH; Wang JL; Chiang WC; Lai MS; Chie WC; Chang SC; Hsueh PR
J Antimicrob Chemother; 2014 Jan; 69(1):211-8. PubMed ID: 23997017
[TBL] [Abstract][Full Text] [Related]
55. Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: the role of empiric antibiotic therapy.
Gómez J; García-Vázquez E; Baños R; Canteras M; Ruiz J; Baños V; Herrero JA; Valdés M
Eur J Clin Microbiol Infect Dis; 2007 Apr; 26(4):239-45. PubMed ID: 17318479
[TBL] [Abstract][Full Text] [Related]
56. Effect of vancomycin initial dosing on time to systemic inflammatory response syndrome resolution in patients with methicillin-resistant Staphylococcus aureus bacteremia.
Wesolek JL; McNorton K; Delgado G; Giuliano CA
J Chemother; 2018 Apr; 30(2):101-106. PubMed ID: 29065784
[TBL] [Abstract][Full Text] [Related]
57. Influence of teicoplanin MICs on treatment outcomes among patients with teicoplanin-treated methicillin-resistant Staphylococcus aureus bacteraemia: a hospital-based retrospective study.
Chang HJ; Hsu PC; Yang CC; Siu LK; Kuo AJ; Chia JH; Wu TL; Huang CT; Lee MH
J Antimicrob Chemother; 2012 Mar; 67(3):736-41. PubMed ID: 22169187
[TBL] [Abstract][Full Text] [Related]
58. Vancomycin MICs do not predict the outcome of methicillin-resistant Staphylococcus aureus bloodstream infections in correctly treated patients.
Rojas L; Bunsow E; Muñoz P; Cercenado E; Rodríguez-Créixems M; Bouza E
J Antimicrob Chemother; 2012 Jul; 67(7):1760-8. PubMed ID: 22556382
[TBL] [Abstract][Full Text] [Related]
59. Factors influencing the clinical outcome of methicillin-resistant Staphylococcus aureus bacteraemia.
Albur MS; Bowker K; Weir I; MacGowan A
Eur J Clin Microbiol Infect Dis; 2012 Mar; 31(3):295-301. PubMed ID: 21667352
[TBL] [Abstract][Full Text] [Related]
60. Time to First Culture Positivity Among Critically Ill Adults With Methicillin-Resistant
Melling PA; Noto MJ; Rice TW; Semler MW; Stollings JL
Ann Pharmacother; 2020 Feb; 54(2):131-137. PubMed ID: 31544471
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
